Article

Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study

2022-08-25

Abstract excerpt

Molnupiravir and Nirmatrelvir are the first available oral antivirals (OA) active against SARS-CoV-2. However, the trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating. The purpose of this study is to provide real-life data on the efficacy and safety of OAs during the omicron surge of COVID-19 pandemic in a cohort of mostly vacci...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 84f8499b-9c6e-5a9e-89a1-912375e500ef
DOI: 10.1101/2022.08.23.22278585

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studyDOI 10.1101/2022.08.23.22278585Read

Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 community, highly vaccinated patients with high risk for severe disease: Evidence that both antivirals reduce the risk for disease progression and deathSemantic proximity Read

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity Read

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity Read

Molnupiravir Use and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational StudySemantic proximity Read

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studySemantic proximity Read

Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity Read

Effect of oral nirmatrelvir on Long COVID symptoms: a case seriesSemantic proximity Read

Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in JapanSemantic proximity Read